2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO, CA
Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
Senti Biosciences Enters $40 Million Securities Purchase Agreement
Other Events
Financial Results, Press Release
Lease Amendment - Senti Biosciences Reduces Leased Premises Size
Investor Presentation
Senti Bio Q3 2025 Financial Results and Next Clinical Data for SENTI-202 Study
Q1
Amended Annual Report
FY 2025
Q3
Q2
FY 2024
Notice of Suspension of Duty to File Reports
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
S-8 POS
Current Report for Successor Issuer